[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatic-cancer":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,66,99,132,177,204,228,260],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":38,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100632708","phase-1-dose-determining-study-of-exs74539-rec-4539-in-participants-with-select-solid-tumors-100632708",false,"NCT07517198","Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors","A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors","Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically confirmed diagnosis of the following solid tumors:\n\n  * SCLC\n  * High grade neuroendocrine or small cell carcinomas of non-lung origin\n  * Non-small cell lung cancer \\[NSCLC\\]\n  * Prostate cancer\n  * Ovarian cancer\n  * Renal carcinoma \\[clear and non-clear cell\\]\n  * Head and neck squamous cell carcinoma\n  * Hepatic cancer\n  * Gastric cancer\n  * Triple-negative breast cancer \\[TNBC\\]\n* Participant disease should have progressed, relapsed or the participants should have been intolerant to at least one prior standard systemic therapy for their respective underlying malignancy.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n\nKey Exclusion Criteria:\n\n* Any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.\n* Symptomatic brain metastases, leptomeningeal metastases, or spinal cord compression due to disease. Participants with brain metastases must be clinically stable and off corticosteroids and anticonvulsants for ≥1 month prior to study treatment and not require any specific intervention for brain metastases.\n* Active and clinically significant infection requiring systemic antibacterial, antiviral, or antifungal therapy \\\u003C7 days of the first scheduled dose of the study treatment.\n* Significant cardiac abnormalities.\n* Major surgery within 28 days prior to the start of study treatment.\n\nNote: Other protocol-defined inclusion and exclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.",[26,27,28,29,30,31,32,33,34,35,36,37],"Solid Tumor","Small Cell Lung Cancer (SCLC)","High Grade Neuroendocrine Cancer","Small Cell Carcinomas of Non-lung Origin","Non-small Cell Lung Cancer (NSCLC)","Prostate Cancer","Ovarian Cancer","Renal Carcinoma (Clear and Non-clear Cell)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Hepatic Cancer","Gastric Cancer","Triple-negative Breast Cancer (TNBC)",[39,27,40,41,42,43,44,45,46,47,48,49,50,51,52],"Solid Tumors","High grade neuroendocrine cancer","Small cell carcinomas of non-lung origin","Non-small cell lung cancer (NSCLC)","Prostate cancer","Ovarian cancer","Renal carcinoma (clear and non-clear cell)","Head and neck squamous cell carcinoma (HNSCC)","Hepatic cancer","Gastric cancer","Triple-negative breast cancer (TNBC)","LSD1 inhibitor","EXS74539","REC-4539","RECRUITING","2026-06-09",{"date":56,"type":57},"2026-06-10","ACTUAL",{"date":59,"type":57},"2026-04-13",{"date":61,"type":20},"2029-03",{"name":63,"class":64},"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.","INDUSTRY",3,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":84,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100542403","an-exosome-based-liquid-biopsy-for-the-differential-diagnosis-of-primary-liver-cancer-100542403","NCT06342414","An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer","ELUCIDATE","Inclusion Criteria:\n\n* A histologically confirmed diagnosis of hepatocellular carcinoma\n* A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma\n* Received standard diagnostic and staging procedures as per local guidelines\n* Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment\n\nExclusion Criteria:\n\n* Lack of or inability to provide informed consent\n* Synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma\n* Primary liver cancer other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma\n* Secondary liver cancer",{"count":74,"type":20},400,"OBSERVATIONAL","It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.",[78,79,80,81,82,35,83],"Hepatocellular Carcinoma","Intrahepatic Cholangiocarcinoma","Cholangiocarcinoma","Primary Liver Cancer","Primary Liver Carcinoma","Hepatic Carcinoma",[85,86,87],"Exosome","micro RNA","Differential Diagnosis","2026-04-01",{"date":90,"type":57},"2026-04-03",{"date":92,"type":57},"2024-03-15",{"date":94,"type":20},"2026-06-18",{"name":96,"class":97},"City of Hope Medical Center","OTHER",5,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":109,"conditions":110,"keywords":117,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100565112","comparison-of-the-diagnosis-time-of-vet-and-scl-in-patients-with-intraoperative-coagulopathy-100565112","NCT06637943","Comparison of the Diagnosis Time of VET and SCL in Patients With Intraoperative Coagulopathy","Comparison of Time Taken for Diagnosing Intraoperative Coagulopathies: Point-of-care Viscoelastic Tests vs Standard Central Laboratory Tests","Inclusion Criteria:\n\n* patients who will undergo elective surgery with a high risk of moderate to severe amount of intraoperative bleeding or coagulopathy (e.g., cardiac surgery, joint replacement, spine surgery, hepatectomy, radical prostatectomy)\n* patients who provide written informed consent\n* patients who may warrant the intraoperative use of POC viscoelastic test or SCL test\n\nExclusion Criteria:\n\n* pregnancy\n* withdrawal of consent\n* termination of surgery without performing either POC viscoelastic test or SCL tests\n* when the study conductor deems it inappropriate to proceed with the protocol with the patient","19 Years",{"count":108,"type":20},210,"The present study is a prospective, multi-center observational trial comparing the times taken to diagnose coagulopathies using point-of-care (POC) viscoelastic tests or standard central laboratory tests (SCL tests) in patients with intraoperative bleeding.",[111,112,113,31,35,114,115,116],"Arthritis of Knee","Arthritis of Hip","Spine","Valvular Disorder","Ischemic Heart Disease","Aortic Diseases",[118,119,120],"viscoelastic test","standard central laboratory test","coagulation","NOT_YET_RECRUITING","2025-12-01",{"date":124,"type":57},"2025-12-08",{"date":126,"type":20},"2026-02-01",{"date":128,"type":20},"2026-05-31",{"name":130,"class":97},"Konkuk University Medical Center",4,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":145,"conditions":146,"keywords":157,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100572340","optimal-perioperative-pain-control-in-minimally-invasive-abdominal-cancer-surgery-100572340","NCT06731998","Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery","Evaluating Optimal Perioperative Pain Management: A Prospective Randomized Control Trial of Laparoscopic Transversus Abdominis Plane Block With Local Anesthetic, Laparoscopic Transversus Abdominis Plane Block Alone, and Local Anesthetic Alone in Minimally Invasive Oncologic Surgery","LapTAP","Inclusion Criteria:\n\n1. Male and female patients age ≥ 18 - 89\n2. Patients scheduled for elective (clinically indicated) hepatic, gastric, biliary, pancreatic, gynecologic, colorectal, other GI Minimally invasive oncologic surgery.\n3. Patients who have provided informed consent to participate in the study.\n4. Patients with an American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.\n5. Patients undergoing procedures anticipated to last more than 1 hour but less than 8 hours.\n6. Patients able to understand and self-report pain using the designated pain Visual Analog Scale\n\nExclusion Criteria:\n\n1. Patients age less than 18 or ≥ 90\n2. Pre-existing hepatic dysfunction, cirrhosis\n3. Patients with an ASA classification of IV or higher.\n4. Patients with chronic pain disorders or on long-term opioid or analgesic therapy.\n5. Patients with known contraindications to the study drugs or procedures (e.g., allergy to LA or contraindications to LapTAP).\n6. Patients with cognitive impairments or psychiatric conditions that could interfere with pain assessment or understanding of informed consent.\n7. Patients unable to understand the language in which consent and study-related information are provided (The study and the study-related information will be in the English Language)..\n8. Patients who have undergone major surgery within the last 6 months.\n9. Female patients who are pregnant.\n10. Patients currently enrolled in another clinical trial that might interfere with the outcome measures of this study.","89 Years",{"count":142,"type":20},48,[144],"NA","This is a research study to evaluate the effectiveness of 3 different types of routine pain management regimens used during clinically indicated, minimally invasive oncologic (cancer) surgery. This project is considered \"Research\" and participation is voluntary. Upon enrollment in this study, the research team will collect data from the patient's medical records. The patient will undergo all of the normal testing and procedures required pre-operatively (standard of care). The study team will then randomly assign the patient (like a flip of a coin) to one of three different study arms for pain management during surgery:\n\n1. Laparoscopic Transversus Abdominis Plane Block (LapTAP) with Local Anesthetic (LA)\n2. Laparoscopic Transversus Abdominis Plane Block (LapTAP) only\n3. Local Anesthetic (LA) only The patient will receive standard pre- and post-operative care according to clinical guidelines (routine care). The study team will collect information from the patient's medical record for the first 24 hours after their surgery and upon discharge. This information will include pain scores, amount of medication required, any side effects the patient may have experienced, and satisfaction with pain control. Participation in the study will end upon discharge from the hospital.",[147,148,149,35,150,151,152,153,154,155,156],"Oncologic Surgery","Cancer","Cancer Surgery","Gastric (Cardia, Body) Cancer","Biliary Tract Cancer","Pancreatic Cancer Resectable","Gynecologic Cancers","Gastrointestinal Cancers","Colorectal Cancer","Minimally Invasive Surgical Procedures",[158,159,160,161,162,163,164,165,166],"Laparoscopic Transversus Abdominis Plane Block","Local Anesthetic","Laparoscopic Surgical Procedure","pain management","cancer","cancer surgery","oncologic surgery","perioperative pain management","minimally invasive surgical procedures","2025-09-15",{"date":169,"type":57},"2025-09-18",{"date":171,"type":57},"2025-02-05",{"date":173,"type":20},"2026-12",{"name":175,"class":97},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",1,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":185,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":176},"100592492","seravue-validation-study-for-hepatocellular-carcinoma-hcc-diagnosis-100592492","NCT06994130","Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis","A Prospective Evaluation of Seravue Device Sensitivity and Specificity for Surveillance and Diagnosis of Patients at Risk for Hepatocellular Carinoma (HCC)","Seravue","INCLUSION\u002FEXCLUSION CRITERIA:\n\nPatients who provide written informed consent and meet eligibility criteria will undergo baseline assessments and be entered into the study.\n\nInclusion Criteria:\n\nA patient must meet all of the following criteria to be eligible for this study:\n\n1. The patient is willing and able to provide signed informed consent.\n2. The patient is aged ≥21to ≤84 years.\n3. The patient is willing to undergo phlebotomy and provide blood samples for future biomarker analysis.\n4. The patient is willing and able to undergo regularly scheduled onsite liver cancer surveillance by ultrasound and AFP and any resulting axial imaging such as computed tomography (CT, with or without contrast), magnetic resonance imaging (MRI), or ultrasound per the standard of care guidelines and study protocol schedule.\n5. The patient has been diagnosed with hepatic cirrhosis of any etiology (both viral and non-viral), or Hepatitis B Virus (HBV). This includes HBV patients with pre-existing cirrhosis prior to antiviral therapy or other treatments leading to fibrosis regression who continue to be at risk.\n\n   a. Cirrhosis may be diagnosed by any one of the following three methods: i. Biopsy and histological examination ii. Fibroscan (VCTE ≥ 12.5kPa) for all etiologies except HBV), Magnetic resonance elastography (≥ 4 kPa) iii. A combination of imaging (MRI, CT, or ultrasound) demonstrating a cirrhotic appearing liver AND at least one of the following:\n\n1\\. Thrombocytopenia 2. Clinical symptoms (including but not limited to ascites, portal hypertension, hypersplenism, esophageal varices, and encephalopathy).\n\n6\\) The patient has been diagnosed with HBV without cirrhosis.\n\n1. HBV will be defined by either a positive blood test for HBsAg, quantitative HBsAg, HBeAg OR detectable HBV DNA prior to initiating antiviral therapy.\n2. Patients are:\n\ni. Asian males ≥ 40 years old OR ii. Asian females ≥ 50 years old OR iii. Patients of any ethnicity with a page B score ≥ 10\n\nExclusion Criteria\n\nA patient who meets any of the following criteria will be excluded from this study:\n\n1. Any health condition or other reason which, in the opinion of the investigator, would prelude study participation.\n2. Current Child Pugh C cirrhosis\n3. The patient has previously been diagnosed with a primary liver cancer or any cancer that has metastasized.\n4. The patient has participated in an interventional clinical study within 30 days prior to screening in which an experimental treatment was administered.\n5. The patient is unable or unwilling to submit to phlebotomy for testing or undergo ultrasound or other diagnostic imaging such as contrast-enhanced CT or MRI as recommended by AASLD standard of care guidelines.\n6. The patient would not routinely be recommended for HCC surveillance.\n7. The female patient is pregnant or plans to become pregnant during the study.\n8. History of solid nodule on baseline ultrasound (i.e., lesion 1cm or greater) within 9 months prior to consent without subsequent diagnostic multi-phase CT\u002FMRI demonstrating benign nature\n9. AFP \\>20 ng\u002FmL within 6 months prior to consent, in the absence of a contrast-enhanced multi-phase CT or MRI (before or after) in the past year demonstrating lack of suspicious liver lesions.\n\n   a. If the AFP is \\>20 ng\u002FmL during the study, the patient should undergo a contrast-enhanced multi-phase CT or MRI. if the patient has consistent elevations that are not increasing, repeat diagnostic testing will be left to the discretion of the investigator or the faculty.\n10. History of LR-4, LR-5, or LR-M on multi-phase CT or contrast-enhanced MRI prior to consent\n11. Patient's provider is planning to use only MRI- or CT- based surveillance moving forward\n12. History of Fontan associated liver disease or cardiac cirrhosis\n13. Actively listed for liver transplantation","21 Years","84 Years",{"count":188,"type":20},1392,"Currently, ultrasound with or without AFP is the standard of care when it comes to surveillance for HCC in high-risk populations. While ultrasound is non-invasive and plays a critical role in detecting HCC, it is operator-dependent, inconvenient, and may have access issues in low-resource settings. Most critically, ultrasound is not sensitive enough to detect or confirm HCC in its most critical early stages, where treatment options are most effective and result in the best patient outcomes. AFP on the other hand, suffers from poor sensitivity and specificity generally, and its performance is insufficient for use as a surveillance tool. There remains a clear unmet need for a blood test that is sensitive enough to detect HCC in its early stages while being cost-effective and accessible for use as a surveillance tool.\n\nThe investigators have previously demonstrated that serum liver cancer-secreted serine protease inhibitor Kazal (LC-SPIK) can reliably detect early HCC in addition to differentiating between it and other liver diseases. This study seeks to test the performance of the Seravue (LC-SPIK) device alone or in combination with other HCC diagnostic tests as a tool for HCC surveillance in diverse patient populations and clinical settings.",[35],[192,193,194],"liver cancer","AFP","ultrasound","2025-05-29",{"date":197,"type":57},"2025-06-04",{"date":199,"type":20},"2025-08",{"date":201,"type":20},"2029-08",{"name":203,"class":64},"ImCare Biotech",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":176},"100571277","immunohistochemical-algorithm-for-the-diagnosis-and-classification-of-hepatocellular-carcinomas-with-tert-tp53-and-ctnnb1-mutation-100571277","NCT06718153","Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients resected for HCC\n* Availability of NGS data\n* Availability of paraffin material for immunohistochemistry investigations\n\nExclusion Criteria:\n\n* None",{"count":211,"type":20},100,[144],"The presence of certain mutations in HCC, such as TERT and TP53, have a suspected or proven prognostic role in resected patients, but lack a morphological or immunophenotypic counterpart, which would allow us to define which tumours are rationally candidate for molecular biology analysis. The identification of a histological and immunohistochemical algorithm to determine which HCCs to take to NGS for prognostic purposes will save time and economic costs in the laboratory by rationalising available resources. In the future, the application of the immunohistochemical and molecular algorithm on biopsy could allow better prognosis and predictivity even before surgery\u002Ftherapy.",[35,215],"Hepatic Resection",[217,218],"Molecular diagnostics","Immunohistochemistry","2024-12-04",{"date":221,"type":57},"2024-12-05",{"date":223,"type":57},"2024-10-23",{"date":225,"type":20},"2025-06",{"name":227,"class":97},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":238,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":176},"100553924","phase-2-neoadjuvant-intra-tumor-double-immunotherapy-for-hepatocellular-carcinoma-100553924","NCT06492408","Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.","Phase II Study of Neoadjuvant CT-Guided Intra-tumor Double Checkpoint Blockades for Untreated Hepatocellular Carcinoma (HCC) Amenable for Surgical Resection","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed previously untreated hepatocellular carcinoma (HCC). If a diagnostic biopsy is available, a pre-treatment biopsy is not required. Patients with a suspected HCC are eligible, but pathology must be confirmed prior to initiating treatment on study.\n2. The patient must be a suitable candidate for surgery, in the opinion of the treating physician.\n3. Signed and dated written informed consent must be provided by the patient prior to admission to the study in accordance with International Conference on Harmonization-Good Clinical Practice (ICH-GCP) guidelines and to the local legislation.\n4. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1\n5. Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\u002FL; Hemoglobin \\>= 8.0 g\u002FdL; Platelets \\>= 100 x 10\\^9\u002FL; Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN) (except subjects with Gilbert syndrome who can have total bilirubin \\\u003C 3.0 mg\u002FdL); Creatinine =\\\u003C 1.5 x ULN or calculated creatinine clearance \\>= 50 mL\u002Fmin using Cockcroft-Gault formula for creatinine clearance calculation OR 24-hour urine creatinine clearance \\>= 50 mL\u002Fmin.\n6. Birth control.\n7. Willing and able to comply with scheduled visits, treatment plan and laboratory tests.\n\nExclusion Criteria:\n\n1. Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks;\n2. Patients accompany by ascites, hepatic encephalopathy and esophageal and gastric varices bleeding;\n3. Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders;\n4. Patients accompanied with other tumors or past medical history of malignancy;\n5. Pregnant or lactating patients, all patients participating in this trial must adopt appropriate birth control measures during treatment;\n6. Patients have poor compliance. A.Impaired clotting test (platelet count \\\u003C 60000\u002Fmm3, prothrombin activity \\\u003C 50%).\n\n   B.Renal failure \u002F insufficiency requiring hemo-or peritoneal dialysis. C.Known severe atheromatosis. D.Known uncontrolled blood hypertension (\\> 160\u002F100 mm\u002FHg).\n7. Allergic to contrast agent;\n8. Any agents which could affect the absorption or pharmacokinetics of the study drugs\n9. Other conditions that investigator decides not suitable for the trial.","75 Years",{"count":237,"type":20},90,[239],"PHASE2","This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by delivery of CTLA4 and PD1 or PDL1 antibodies combination through CT-guided intra-tumor (IT) injection.",[35,242],"Surgery",[244,245,246,242,247,248,249,250],"Hepatocellular Carcinoma;","Intra-tumor injection","Neoadjuvant therapy","Immunotherapy","CTLA4 antibody","PD1 antibody","PDL1 antibody","2024-07-02",{"date":253,"type":57},"2024-07-09",{"date":255,"type":57},"2024-07-01",{"date":257,"type":20},"2033-12-30",{"name":259,"class":97},"Second Affiliated Hospital of Guangzhou Medical University",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":235,"enrollmentInfo":267,"targetDuration":4,"studyType":21,"phases":269,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":283,"locationsCount":4},"100496906","liver-transplantation-with-two-stage-liver-resection-in-unresectable-liver-cancer--metastases-or-emd-stage-liver-disease-ltlr-lc-100496906","NCT05750329","Liver Transplantation With Two-stage Liver Resection in Unresectable Liver Cancer , Metastases or Emd-stage Liver Disease (LTLR-LC)","Clinical Study of Adjuvant Liver Transplantation Combined With Two-stage Hepatectomy for the Treatment of Patients With Unresectable Primary Hepatocellular Carcinoma, Colorectal Cancer With Liver Metastases, or End-stage Liver Disease: a Multicenter, Prospective, Single-arm Study","Inclusion Criteria:\n\n1. aged 18-75 years;\n2. patients with unresectable primary hepatocellular carcinoma or colorectal cancer with liver metastases who also meet the following criteria: tumor shrinkage (still unresectable) or no significant progression after a first-line chemotherapy regimen of 6-8 weeks; no other abdominal metastases or 1-3 resectable pulmonary metastases;\n3. patients with end-stage liver disease;\n4. preoperative Child classification of A or B, able to tolerate the subsequent surgical program\n5. Signed informed consent Note: One of the second or third criteria needs to be fulfilled and all the rest of the selection criteria need to be fulfilled\n\nExclusion Criteria:\n\n1. Extrahepatic tumor burden (except for resectable lung metastases) and\u002For macrovascular tumor infiltration\n2. Tumor progression during chemotherapy or important comorbidities that affect surgery\n3. Uncorrectable cardiopulmonary disease with high surgical risk\n4. Anatomical abnormalities that preclude liver transplantation\n5. Persistent non-compliance with medical care\n6. Combined with other diseases such as AIDS that affect surgery or tumor progression",{"count":268,"type":20},30,[144],"Colon cancer and primary liver cancer are common malignant tumors with low survival rate worldwide, and unresectable primary liver cancer and colon cancer liver metastases have worse prognosis. End-stage liver disease is equated with advanced liver disease, liver failure and decompensated cirrhosis because they are generally irreversible. Liver transplantation is a treatment option for the above-mentioned patients and is expected to improve the prognosis of the patients, but the biggest problem faced by such patients is the shortage of donor livers. Recently, a new surgical modality, resection and partial liver segment 2-3 transplantation with delayed total hepatectomy (RAPID), can greatly alleviate these problems.Based on clinical surgical experience, our center proposes and designs a clinical study of adjuvant liver transplantation combined with two-stage hepatectomy in the treatment of patients with unresectable primary liver cancer, colorectal cancer liver metastases, or end-stage liver disease. By improvement of RAPID operation, the safety and efficacy of this treatment method in patients with those disease were evaluated.",[272,35,273],"Liver Transplant Disorder","End-stage Liver Disease",[275,276],"liver transplantation","Hepatectomy","2023-08-03",{"date":279,"type":57},"2023-08-07",{"date":281,"type":20},"2023-08",{"date":173,"type":20},{"name":284,"class":97},"RenJi Hospital"]